Cargando…

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors

Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manasa, Justen, Varghese, Vici, Pond, Sergei L. Kosakovsky, Rhee, Soo-Yon, Tzou, Philip L., Fessel, W. Jeffrey, Jang, Karen S., White, Elizabeth, Rögnvaldsson, Thorsteinn, Katzenstein, David A., Shafer, Robert W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599673/ https://www.ncbi.nlm.nih.gov/pubmed/28912582 http://dx.doi.org/10.1038/s41598-017-11893-8

Ejemplares similares

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
por: Tzou, Philip L., et al.
Publicado: (2018)

HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing
por: Tao, Kaiming, et al.
Publicado: (2023)

Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
por: Tzou, Philip L., et al.
Publicado: (2022)

Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population
por: Rhee, Soo-Yon, et al.
Publicado: (2019)

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
por: Blanco, Jose-Luis, et al.
Publicado: (2011)

Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
por: Tao, Kaiming, et al.
Publicado: (2022)

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2021)

Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences
por: Tzou, Philip L., et al.
Publicado: (2020)

Sierra SARS-CoV-2 sequence and antiviral resistance analysis program
por: Tzou, Philip L., et al.
Publicado: (2022)

Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation
por: Varghese, Vici, et al.
Publicado: (2010)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
por: Babrzadeh, Farbod, et al.
Publicado: (2013)

Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA)
por: Kouamou, Vinie, et al.
Publicado: (2021)

National and International Dimensions of Human Immunodeficiency Virus-1 Sequence Clusters in a Northern California Clinical Cohort
por: Rhee, Soo-Yon, et al.
Publicado: (2019)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

The biological and clinical significance of emerging SARS-CoV-2 variants
por: Tao, Kaiming, et al.
Publicado: (2021)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

Controlling ion sources with Artiflcial Neural Networks
por: Peterson, Carsten, et al.
Publicado: (1992)

A review of explainable AI in the satellite data, deep machine learning, and human poverty domain
por: Hall, Ola, et al.
Publicado: (2022)

Evaluation of global HIV/SIV envelope gp120 RNA structure and evolution within and among infected hosts
por: Rife Magalis, Brittany, et al.
Publicado: (2018)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles
por: Meador, Lydia R., et al.
Publicado: (2017)

Gp41 and Gag amino acids linked to HIV‐1 protease inhibitor‐based second‐line failure in HIV‐1 subtype A from Western Kenya
por: Coetzer, Mia, et al.
Publicado: (2017)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Functional conservation of HIV-1 Gag: implications for rational drug design
por: Li, Guangdi, et al.
Publicado: (2013)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag–protease genes
por: Sutherland, Katherine A., et al.
Publicado: (2014)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope
por: Penn-Nicholson, Adam, et al.
Publicado: (2008)

Correction: Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Antiviral properties of two trimeric recombinant gp41 proteins
por: Delcroix-Genête, Delphine, et al.
Publicado: (2006)

Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles
por: Kessans, Sarah A., et al.
Publicado: (2016)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
por: Strokappe, Nika M., et al.
Publicado: (2019)

Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
por: Guenaga, Javier, et al.
Publicado: (2011)

Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences
por: Rhee, Soo-Yon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_adj8bjpi5g3ecu5jevluo43jei